Looking for people's feedback on Specialty Pharma and Generics. Is Specialty Pharma more about policy/regulation stuff? I'd rather steer clear of groups where a lot of the research is based on what happens in Washington. Any comments would be great!
| +13 | Is Equity Research Dying - Where Are the Future Opportunites? | 4 | 1d |
| +10 | Associates who stuck around for > 5 years working for the same analyst. Why? | 4 | 6d |
| +9 | UBS ER SA27 Superday | 7 | 3w |
| +9 | Detailed Revenue and Cost Builds | 3 | 1w |
| +7 | Analyst with no coverage or ranking | 5 | 1w |
| +7 | Uiuc or Ross or UChicago | 8 | 3w |
| +1 | IB SA -> ER FT | 4 | 2w |
| 0 | Equity Research Rankings | 1 | 1w |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
I work in spec pharma/generics for a BB and there is a ton of policy stuff you have to follow. Very different from a pure biotech research position. Caveat Emptor
Would you ever move to a pure biotech research position then? Did you start your job out of undergrad/summer internship?
Would love to hear your best long ideas, if any, right now.
Since the MOA is often well-understood for spec pharma and generics drugs, there's much less uncertainty with respect to the science than in biotech. It's focused more on the market opportunity, M&A, and forward-looking regulatory environment.
Quo sint voluptatibus commodi nihil nostrum debitis sapiente laudantium. Repudiandae totam quasi veniam laudantium similique deserunt. Et nihil qui praesentium quia et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...